Endoplasmic Reticulum D-myo-Inositol 1,4,5-Trisphosphate-sensitive Stores Regulate Nuclear Factor-kappa B Binding Activity in a Calcium-independent Manner*

Gordon W. GlaznerDagger §, Simonetta CamandolaDagger , Jonathan D. Geiger§, and Mark P. MattsonDagger ||**

From the Dagger  Laboratory of Neurosciences, NIA Gerontology Research Center, National Institutes of Health, Baltimore, Maryland 21224, the § Department of Pharmacology and Therapeutics, University of Manitoba Faculty of Medicine, Winnipeg, Manitoba R3E 0T6, Canada, and the || Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205

Received for publication, February 12, 2001

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The transcription factor nuclear factor-kappa B (NF-kappa B) plays critical roles in neuronal survival and plasticity and in activation of immune responses. The activation of NF-kappa B has been closely associated with changes in intracellular calcium levels, but the relationship between the two remains unclear. Here we report that inhibition of endoplasmic reticulum (ER) D-myo-inositol 1,4,5-trisphosphate (IP3)-gated calcium release caused decreased basal NF-kappa B DNA-binding activity in cultured rat cortical neurons. Activation of NF-kappa B in response to tumor necrosis factor-alpha and glutamate was completely abolished when IP3 receptors were blocked, and NF-kappa B activation in response to depletion of ER calcium by thapsigargin treatment was also decreased by IP3 receptor blockade. We further investigated the relationship between IP3 receptor activation and NF-kappa B activity using a cell-free system. Microsomes enriched in the ER were isolated from adult rat cerebral cortex, resuspended, and treated with agents that induce or inhibit ER calcium release. They were then recentrifuged, and the supernatant was added to cytoplasmic extract isolated from the same source tissue. We found that microsomes released an NF-kappa B-stimulating signal in response to activation of IP3 receptors or inhibition of the ER Ca2+-ATPase, but not in response to ryanodine. Studies of intact cells and cell-free preparations indicated that the signal released from the ER was not calcium and was heat- and trypsin-sensitive. Our data suggest that activation of IP3 receptors is required for a major component of both constitutive and inducible NF-kappa B binding activity in neurons and that decreasing ER intraluminal calcium levels triggers release of a diffusible NF-kappa B-activating signal from the ER.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The transcription factor NF-kappa B1 is a member of the NF-kappa B/Rel family, which includes p50, p52, p65 (RelA), c-Rel, and RelB proteins (1, 2). Prototypical NF-kappa B is a p50-p65 heterodimer that is retained in the cytoplasm of unstimulated cells in an inactive form by the inhibitory protein Ikappa Balpha . In response to various stimuli, Ikappa Balpha is phosphorylated, rapidly ubiquitinated, and subsequently proteolyzed by a 26 S proteasome complex. The degradation of Ikappa Balpha unmasks the nuclear localization signal of the NF-kappa B heterodimer, which then translocates into the nucleus, where it binds to its cognate sequence on DNA and thereby regulates gene transcription. In the brain, NF-kappa B is constitutively active in many neurons (3), wherein its activity may be further increased by excitation (4, 5) and ischemia (6, 7) and in neurodegenerative disorders (8-10). Because activation of NF-kappa B is associated with cell injury and death, it has been proposed that this transcription factor contributes to the neuronal death process (6, 11). However, results from cell culture and in vivo studies have demonstrated that activation of NF-kappa B in neurons represents a highly protective response that promotes cell survival and plasticity (12-16).

Stimuli that can activate NF-kappa B include TNF-alpha (12, 17, 18), interleukin-1beta (19), glutamate (20), nerve growth factor (21, 22), and secreted amyloid precursor protein (23). Increased NF-kappa B activity may also occur in response to oxidative stress, perturbed calcium homeostasis, and DNA damage (2, 24-26). However, the mechanisms that regulate NF-kappa B activity in neurons under basal conditions and in response to various physiological and pathological conditions are not known. Changes in the concentration of intracellular free calcium ([Ca2+]i) regulate numerous functions in neurons, including synaptic plasticity and cell survival (27, 28). Influx through the plasma membrane has long been regarded as the main source of Ca2+-mediated intracellular signals. However, the significance of Ca2+ released from internal stores such as the ER has become increasingly apparent. In neurons, the ER is distributed throughout the cytoplasm and represents a large and releasable pool of calcium. Increased [Ca2+]i can stimulate release of Ca2+ stored in the ER, a phenomenon known as calcium-dependent calcium release that is regulated by the ER-resident IP3- and ryanodine-sensitive receptor calcium channels (29). The intracellular signaling molecule IP3, the ligand for ER IP3 receptors, is generated by activation of phospholipase C and cleavage of phosphoinositol bisphosphate into diacylglycerol and IP3. Calcium regulates the sensitivity of these channels to IP3, increasing the calcium current (28). Therefore, alterations in [Ca2+]i will affect the activity of the ER IP3 receptor and thus affect cellular events regulated by this receptor.

Recent studies have shown that impairment of ER function with accumulation of proteins in the ER and the consequent release of Ca2+ from this organelle stimulates NF-kappa B DNA-binding activity and NF-kappa B-dependent gene expression (30, 31). Because IP3 receptors are highly sensitive to many of the same stimuli that activate NF-kappa B, and alterations in ER function are associated with increased NF-kappa B binding and transcription, we examined the relationship between ER IP3 receptors and NF-kappa B activation.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Cortical Cell Cultures and Experimental Treatments-- Cerebral cortices were removed from embryonic day 18 Harlan Sprague-Dawley rats (Harlan Sprague Dawley, Inc., Indianapolis, IN). Cells were dissociated by mild trypsinization and trituration as described previously (32) and were seeded into 60-mm polyethyleneimine-coated culture dishes containing Eagle's minimum essential medium supplemented with 26 mM NaHCO3, 40 mM glucose, 20 mM KCl, 1 mM sodium pyruvate, 10% (v/v) heat-inactivated fetal bovine serum (Sigma), and 0.001% gentamycin sulfate. After a 3-5-h incubation period to allow for cell attachment, the medium was replaced with 2 ml of neurobasal medium with B27 supplements (Life Technologies, Inc.). Experimental treatments were performed on 7-9-day-old neuronal cultures in which ~95% of the cells were neurons and the remaining cells were astrocytes. IP3, glutamate, and ryanodine were purchased from Sigma; xestospongin C (XeC) was purchased from Calbiochem; TNF-alpha was purchased from Pepro-Tech Inc. (Rocky Hill, NJ); and thapsigargin and BAPTA free acid were purchased from Molecular Probes, Inc. (Eugene, OR). Each reagent was prepared as a 500× or 1000× stock in an appropriate solvent (saline or dimethyl sulfoxide).

Total Cell Extract Preparation and Electrophoretic Mobility Shift Assay (EMSA)-- Total cell extracts were prepared as described (33). Briefly, cells were harvested, washed twice with ice-cold phosphate-buffered saline, and lysed for 30 min at 4 °C in Totex buffer (350 mM NaCl, 20% glycerol, 1% Nonidet P-40, 1 mM MgCl2, 0.5 mM EDTA, 0.1 mM EGTA, 5 mM dithiothreitol, 0.1% phenylmethylsulfonyl fluoride, 1% aprotinin, 4 µg/ml leupeptin, and 20 mM HEPES, pH 7.9). Samples were centrifuged at 14,000 × g for 10 min, and aliquots of the supernatant were collected and stored at -70 °C until taken for assay. The protein content of the extract (supernatant) was measured by the Bradford method (Bio-Rad). For EMSA, equal amounts of protein were incubated in a 20-µl reaction mixture containing 20 µg of bovine serum albumin; 1 µg of poly(dI-dC); 2 µl of buffer containing 20% glycerol, 100 mM KCl, 0.5 mM EDTA, 0.25% Nonidet P-40, 2 mM dithiothreitol, 0.1% phenylmethylsulfonyl fluoride, and 20 mM HEPES, pH 7.9; 4 µl of buffer containing 20% Ficoll 400, 300 mM KCl, 10 mM dithiothreitol, 0.1% phenylmethylsulfonyl fluoride, and 100 mM HEPES, pH 7.9; and 20,000-50,000 cpm of 32P-labeled oligonucleotide (Promega, Madison, WI) corresponding to either an NF-kappa B-binding site (5'-AGT TGA GGG GAC TTT CCC AGG C-3') or a CREB-binding site (5'-AGA GAT TGC CTG ACG TCA GAG AGC TAG-3'). After 20 min at room temperature, reaction products were separated on a 7% nondenaturing polyacrylamide gel. Competition experiments were performed by incubating extracts with labeled oligonucleotide probe in the presence of 100-fold excess unlabeled NF-kappa B, CREB, or AP-1 oligonucleotide. To characterize the NF-kappa B complexes, supershift assays were performed. Extracts were preincubated for 45 min at room temperature with antibodies recognizing either p50 or p65 subunits of NF-kappa B (Santa Cruz Biotechnology, Santa Cruz, CA). The mixtures were further incubated with 32P-labeled probe and resolved as described above. Radioactivity of dried gels was detected by exposure to Kodak X-Omat film, and images on the developed film were scanned into a computer using a UMAX 1200s scanner. Densitometry was performed using Image software (Scion Corp., Frederick, MD). Paint Shop Pro software (Jasc Inc., Minneapolis, MN) was used for preparation of the final figures.

Preparation of Cytoplasmic and Microsomal Fractions-- Cerebral cortices from adult female Harlan Sprague-Dawley rats were homogenized (20 strokes at 300 rpm) with a Teflon homogenizer in ice-cold buffer containing 1 mM EDTA, 0.32 M sucrose, 0.1 mM dithiothreitol, and 1 mM HEPES, pH 7.4, as described previously (34), and cytoplasmic and microsomal fractions were isolated by differential centrifugation. Briefly, tissue fragments and cellular debris were removed by centrifugation at 500 × g for 10 min, and supernatants were centrifuged at 20,000 × g for 20 min to pellet intact mitochondria and nuclei. The supernatant was then centrifuged at 100,000 × g for 1 h to obtain the cytoplasmic fraction and the microsomal pellet enriched in ER and Golgi membranes. Microsomal extracts (MSEs) were prepared by suspending microsomes in ice-cold buffer (1:100, v/v) and centrifuging at 100,000 × g for 1 h. Microsomes were then resuspended in buffer (1:2, v/v) and treated with various agents that affect ER calcium release. At the end of the treatment, the suspension was centrifuged at 100,000 × g for 1 h, and supernatants were used as MSEs. For experiments involving incubation of MSE with the cytoplasmic extract, 3 µl of MSE was added to 10 µl of cytoplasmic extract, and mixtures were incubated at room temperature for 1 h.

Immunoblot Analysis and Measurement of Intracellular Free Calcium Levels-- Immunoblot analyses were performed using methods described previously (35). Briefly, lanes of a 15% acrylamide gel were loaded with cell homogenate, and proteins (100 µg of protein/lane) were separated by electrophoresis and transferred to a nitrocellulose sheet. The nitrocellulose sheet was reacted with primary antibody against grp78 (1:4000 dilution; Stressgen, Inc.), and the primary antibody was detected using horseradish peroxidase-conjugated secondary antibody (1:20,000 dilution; Jackson ImmunoResearch Laboratories, Inc.) and a chemiluminescence-based detection kit (ECL kit, Amersham Pharmacia Biotech). [Ca2+]i in cultured neurons was quantified by fluorescence imaging of the calcium indicator dye fura-2 as described previously (32). Briefly, cells were incubated for 30 min in the presence of 2 µM fura-2 acetoxymethyl ester (Molecular Probes, Inc.), washed with Locke's buffer, and incubated for 40 min prior to imaging. For measurements of the intraluminal Ca2+ concentration, microsomes were incubated for 30 min in the presence of fura-FF acetoxymethyl ester. Cells and microsomes were imaged on a Zeiss Axiovert microscope (40× oil immersion objective) coupled to an Attofluor imaging system. [Ca2+]i in 12-20 neuronal cell bodies or four to six microsomal clusters per microscope field was monitored prior to and after exposure of cells to glutamate.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Inhibition of IP3 Receptor-mediated Calcium Release Decreases and Thapsigargin Increases NF-kappa B Activity in Cortical Neurons-- The possible involvement of ER pools of calcium regulated by IP3 receptors in controlling basal levels of NF-kappa B activation was investigated using XeC, a membrane-permeable blocker of IP3-induced Ca2+ release (36-38). Conversely, to release the total pool of ER luminal calcium, we used thapsigargin, a specific inhibitor of the ER Ca2+-ATPase (39, 40). Cultured primary cortical neurons were treated with 1 µM XeC, 100 nM thapsigargin, or vehicle for 6 h, and protein extracts were analyzed for NF-kappa B DNA-binding activity. XeC caused a significant decrease in the basal levels of activated NF-kappa B relative to control levels (Fig. 1, a and b). The decrease in NF-kappa B activation was not due to interference of XeC with the assay used to detect NF-kappa B activity as determined by addition of XeC to the reaction (data not shown). As previously reported (41), treatment with thapsigargin produced a large and significant increase in NF-kappa B activity (Fig. 1, a and b). To determine if the effects of XeC and thapsigargin were specific for NF-kappa B, we measured the levels of CREB DNA-binding activity. CREB is a transcription factor thought to play a role in synaptic plasticity and neuronal survival (42, 43), and activation of CREB is thought to be primarily regulated by calcium (44). In contrast to their effects on NF-kappa B activity, XeC and thapsigargin each produced a small increase in CREB binding activity (Fig. 1a). We next determined whether IP3 receptor blockade would alter the thapsigargin-induced activation of NF-kappa B. XeC was added to the cortical cultures 30 min before thapsigargin, and binding activity was analyzed after 6 h; IP3 receptor blockade inhibited the ability of thapsigargin treatment to activate NF-kappa B (Fig. 2a).


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 1.   Effects of xestospongin C and thapsigargin on basal levels of NF-kappa B and CREB DNA-binding activities in cerebral cortical cell cultures. a, neurons were treated with vehicle (control (C)), 100 nM thapsigargin (Tg), or 1 µM xestospongin C (X). After 6 h, total cell extracts were prepared, and EMSAs were performed using oligonucleotides specific for NF-kappa B- or CREB-binding sites. b, films from four separate gel-shift assays were scanned, and densitometric analyses were performed. Data are the means ± S.E. (n = 4). *, p < 0.05 versus control (Con) (analysis of variance with Scheffe's post-hoc test).


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 2.   Xestospongin C inhibits induction of NF-kappa B activation. a, shown are the effects of 100 nM thapsigargin in the absence (Tg) or presence (Tg/X) of 1 µM XeC on NF-kappa B DNA-binding activity. b-d, following treatment with either vehicle or 1 µM XeC for 30 min, cells were incubated with TNF-alpha , thapsigargin, or glutamate for 6 h; total cell extracts were prepared; and EMSAs were performed using oligonucleotides specific for NF-kappa B- or CREB-binding sites. b, shown are the effects of 100 ng/ml TNF-alpha in the absence or presence of XeC (X) on NF-kappa B and CREB binding activities. c, films from three separate gel-shift assays of cells treated with vehicle (control (C)), 100 ng/ml TNF-alpha (T), or 1 µM XeC for 30 min prior to TNF-alpha treatment (T+X) were scanned, and densitometric analyses were performed. Data are the means ± S.E. (n = 3). *, p < 0.01 compared with control (Con); #, p < 0.01 compared with TNF-alpha alone (analysis of variance with Scheffe's post-hoc test). d, shown are the effects of 20 µM glutamate in the absence (G) or presence (G/X) of 1 µM XeC on NF-kappa B DNA-binding activity.

Inhibition of IP3 Receptor-mediated Calcium Release Inhibits Inducible NF-kappa B Activity in Cortical Neurons-- NF-kappa B is not only a constitutively active transcription factor, but is also highly inducible in neurons by several stimuli, including the excitatory neurotransmitter glutamate (20, 45, 46) and the pro-inflammatory cytokine TNF-alpha (12). We therefore determined whether activation of IP3 receptor-mediated calcium channels is necessary for NF-kappa B DNA-binding activity induced by glutamate and TNF-alpha . Cells were pretreated for 30 min with vehicle or XeC and were then exposed to 100 ng/ml TNF-alpha or 20 µM glutamate for 6 h. TNF-alpha produced a significant increase in NF-kappa B activity that was completely abolished by pretreatment with XeC (Fig. 2, b and c). This effect was specific for NF-kappa B because neither TNF-alpha nor XeC affected the binding activity of CREB (Fig. 2b). Induction of NF-kappa B DNA-binding activity was observed with glutamate treatment, and pretreatment with XeC completely abolished the activation of NF-kappa B by this excitatory neurotransmitter (Fig. 2d). Cells pretreated with XeC prior to exposure to glutamate demonstrated a level of NF-kappa B activity lower than that of control neurons exposed to glutamate. Measurement of [Ca2+]i in neurons by imaging of the calcium indicator dye fura-2 showed that XeC treatment resulted in only a small attenuation of the glutamate-induced increase in [Ca2+]i. Values were as follows: control, 86 ± 14 nM; 1 µM XeC (5-min exposure), 96 ± 24 nM; 20 µM glutamate (peak response), 618 ± 87 nM; and 1 µM XeC plus 20 µM glutamate (peak response), 410 ± 49 nM (values are the means ± S.D. of determinations made in four cultures with measurements made in at least 12 neurons/culture).

Microsomal Extract Regulates Cytoplasmic NF-kappa B Activity in an ER Calcium Channel-dependent Manner-- Our results to this point indicated that ER IP3-sensitive calcium pools can regulate NF-kappa B activity in neurons. To gain further insight into the mechanism behind this, we used an in vitro cell-free system to separate cytoplasmic pools of inactive NF-kappa B from the ER, therefore allowing us to study ER-derived signals that might modulate NF-kappa B activity. Microsomal preparations were isolated as illustrated (Fig. 3a), and tests were conducted to establish their content of ER. Immunoblot analysis (Fig. 3b) of grp78, an ER-resident chaperone protein, performed on the various fractions demonstrated that the microsomal fraction was highly enriched in this ER marker. Moreover, measurements of the concentration of intramicrosomal calcium and the subsequent reduction in this value with exposure of the microsomes to IP3 demonstrated high levels of functional IP3 receptors in this preparation (Fig. 3c).


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 3.   Subcellular fractionation protocol and characterization of microsomes and cytosolic NF-kappa B proteins. a, shown are the microsomal, MSE, and cytoplasmic extract isolation protocols. XsC, xestospongin C; Thaps, thapsigargin. b, equal amounts of protein from the subcellular fractions were separated by SDS-polyacrylamide gel electrophoresis and probed with an antibody against the ER-resident protein grp78. Similar results were obtained in a separate experiment. Super, supernatant. c, the intraluminal calcium concentration was measured prior to and after exposure to 10 µM IP3. Values (nanomolar) are the average of measurements made in two separate experiments. d, supernatant fractions from the cortex following a 100,000 × g centrifugation for 1 h (cytoplasmic fraction (Cyt)) were incubated for 45 min with anti-p50 antibody (Ab), anti-p65 antibody, or a combination of anti-p50 and anti-p65 antibodies. Binding activity and band position were then analyzed by EMSA. The four sites of NF-kappa B binding identified are referred to as band A (A), band B (B), supershifted band 1 (ss 1), and supershifted band 2 (ss 2).

To determine the identity of the major NF-kappa B-binding complexes found in the cytoplasmic fraction, supernatants from the 100,000 × g centrifugation were incubated with anti-p50 antibody, anti-p65 antibody, or a combination of anti-p50 and anti-p65 antibodies for 45 min. There were two major bands identified in these experiments, bands A and B (Fig. 3d). Addition of anti-p50 antibody shifted band A in its entirety to a much higher position, called supershift 1, and shifted the lower band to a slightly higher position, called supershift 2. Band A was also greatly diminished in intensity by anti-p50 antibody treatment. Incubation with anti-p65 antibody caused a disappearance of band A, but had no apparent effect on band B. Incubation with both anti-p50 and anti-p65 antibodies caused a complete shift upward of band A to the supershift 1 position and shifted band B slightly upwards and reduced its intensity. Thus, band A is the p50-p65 heterodimer, and band B contains p50-p50 homodimers. A binding pattern identical to that seen in the cytoplasmic extracts of this study was previously seen in whole cell extracts of cultured rat cortical neurons (47).

Microsomal preparations were treated with thapsigargin and calcium in the absence or presence of XeC for 1 h and centrifuged, and 3 µl of supernatant (MSE) was added to 10 µl of the cytoplasmic fraction. After 1 h at room temperature, samples were examined for NF-kappa B DNA-binding activity. Significant increases in NF-kappa B activity were observed following addition of MSE, thus indicating the presence of a microsome-derived NF-kappa B-stimulating signal (Fig. 4, a and b). MSE from thapsigargin-treated microsomes caused a significant enhancement of this binding activity (Fig. 4, a and b). MSE from XeC-treated microsomes did not elevate NF-kappa B activity, and treatment with XeC reduced by ~50% the thapsigargin-stimulated NF-kappa B activity (Fig. 4, a and b).


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 4.   Evidence that an NF-kappa B-activating factor is released from the ER in response to calcium release. a, shown are the effects of the microsomal extract on NF-kappa B binding activity. Microsomes were pretreated for 30 min with vehicle or 1 µM XeC (X) and then incubated for 1 h with vehicle (control (C)), 100 nM thapsigargin (Tg), or 10 µM Ca2+. The microsome suspension was centrifuged at 100,000 × g, and 3 µl of MSE was added to 10 µl of cytoplasmic fraction. After incubation for 1 h at 37 °C, NF-kappa B DNA-binding activity was determined. As a control, the cytoplasmic fraction without addition of microsomes (Cyt) was also analyzed. b, exposures from four different experiments were scanned, and densitometry was performed. Data are the means ± S.E. (n = 4). *, p < 0.05, and **, p < 0.01 compared with the cytoplasm alone; +, p < 0.05 compared with thapsigargin alone; #, p < 0.05 compared with cytoplasmic extract/MSE (Cyt/MSE) (analysis of variance with Scheffe's post-hoc test). c, the cytoplasmic fraction, MSE, or pelleted microsomes (Pellet) were treated with vehicle, 1 µM XeC, or 100 nM thapsigargin for 1 h prior to being analyzed for NF-kappa B DNA-binding activity.

A recent report suggested that NF-kappa B may localize to the ER (48), raising the possibility that the NF-kappa B-stimulating agent released by microsomes was the activated transcription factor itself. To examine this possibility, EMSAs were performed on cytoplasmic fractions, MSEs, and microsomal pellets following treatment with vehicle, thapsigargin, or XeC. Although there was binding activity found in MSE and microsomes, this binding was >10-fold less than that seen in the cytoplasm. Neither thapsigargin nor XeC had any effect on NF-kappa B DNA-binding activity levels in any of the three fractions tested (Fig. 4c). We then assessed the necessity of the ER in the microsomal preparation for NF-kappa B activation by treating isolated cytoplasmic extracts from whole adult rat cortices with 100 nM thapsigargin or 1 µM XeC for 1 h at room temperature prior to analysis by EMSA. As shown in Fig. 5a, neither thapsigargin nor XeC directly affected NF-kappa B activity relative to control levels, thus confirming that the presence of the ER is necessary for the activation of NF-kappa B.


View larger version (44K):
[in this window]
[in a new window]
 
Fig. 5.   Activation of NF-kappa B in response to calcium release from the ER is not mediated by calcium itself. a, aliquots of cytoplasmic fractions were left untreated (control (C)) or were treated with 100 nM thapsigargin (Tg) or 1 µM xestospongin C (X) for 1 h, and NF-kappa B DNA-binding activity was determined by EMSA. b, aliquots of cytoplasmic fractions were left untreated (control (Con)) or were treated with calcium at concentrations from 1 µM to 10 mM for 1 h, and NF-kappa B binding activity was determined by EMSA. c, aliquots of cytoplasmic fractions were left untreated or were treated for 1 h with 10 µM Ca2+, 10 µM BAPTA (B), or Ca2+ plus BAPTA, and NF-kappa B DNA-binding activity was determined.

A Signal Other than Calcium Mediates NF-kappa B Activation in Response to ER Calcium Depletion-- We next asked whether NF-kappa B could be induced by calcium directly. Aliquots of the cytoplasmic fraction were treated with calcium at concentrations ranging from 1 µM to 10 mM for 1 h, followed by analysis of NF-kappa B binding by EMSA. As shown in Fig. 5b, calcium did not affect NF-kappa B DNA-binding activity at any concentration tested. These same extracts were analyzed for CREB binding activity; calcium greatly enhanced CREB binding, which likely results from stimulation of calcium-activated kinases (49). These data suggest that although the elevation of calcium in the cytoplasm by itself is able to induce CREB, it is not sufficient to cause NF-kappa B activation. Conversely, chelation of calcium did not produce a decline in NF-kappa B DNA-binding activity. Aliquots of the cytoplasmic fraction were treated for 1 h with 10 µM calcium, a 10 µM concentration of the calcium chelator BAPTA free acid, or a combination of the two. As shown in Fig. 5c, BAPTA alone or in combination with calcium had no effect on the levels of NF-kappa B activity present in the untreated cytoplasm. We next treated microsomes with thapsigargin for 1 h in presence of BAPTA. Calcium chelation did not affect the ability of MSE from thapsigargin-treated microsomes to activate NF-kappa B (Fig. 6a). To test the relative importance of the IP3- and ryanodine-sensitive calcium pools, microsomes were treated with 10 nM ryanodine for 1 h, and then MSE was isolated and added to the cytoplasmic extract for 1 h. The concentration of ryanodine used was based on data in the literature and our previous study demonstrating the presence of functional ryanodine receptors in intact neurons and microsomes from similar neuronal cell cultures (50). MSE from ryanodine-treated microsomes exhibited no greater NF-kappa B-stimulating activity than did MSE from untreated microsomes (Fig. 6a). Since XeC was very effective in blocking NF-kappa B activation, we sought to determine if the NF-kappa B-activating factor could be generated by direct addition of IP3 to microsomes. As shown in Fig. 6 (b and c), IP3 addition led to an increased level of NF-kappa B activity that was similar to that seen with thapsigargin; pretreatment with XeC abolished this effect. Treatment of MSE from IP3-treated microsomes with BAPTA had no effect on the ability of the extract to stimulate NF-kappa B binding in cytoplasmic extracts (data not shown). The NF-kappa B-activating factor released from microsomes was inactivated by heating MSE to 100 °C (Fig. 6, a-c) and was also inactivated by trypsin treatment (Fig. 6a). Collectively, these results indicate that a diffusible factor that is heat- and trypsin-sensitive is released from the ER, in response to stimuli that induce calcium release from IP3-sensitive stores, and is capable of activating NF-kappa B.


View larger version (53K):
[in this window]
[in a new window]
 
Fig. 6.   The NF-kappa B-activating factor released from microsomes is heat-stable and trypsin-sensitive. a, microsome suspensions were treated for 1 h with vehicle (control (C)) or 100 nM thapsigargin after either no pretreatment (Tg) or pretreatment for 30 min with 10 µM BAPTA (Tg/B) (left panel). In a separate experiment, microsome suspensions were treated for 1 h with vehicle or 10 nM ryanodine following either no pretreatment (R) or pretreatment for 30 min with 10 µM XeC (R+X) (right panel). MSE was then added to the cytoplasmic fraction for 1 h, and NF-kappa B binding activity was determined. As a control, an aliquot of the cytoplasmic fraction not exposed to MSE was also analyzed (Cyt). Separate aliquots of MSE from thapsigargin-treated microsomes were either heated at 100 °C for 5 min (Tg/100°) or with trypsin (Tg/T; 0.2%, ~400 units for 5 min at 37 °C; reaction was stopped by addition of 0.2% trypsin inhibitor and transfer in ice). b, microsome suspensions were treated for 1 h with vehicle or 10 µM IP3 following either no pretreatment (IP3) or pretreatment for 30 min with 1 µM XeC (X/IP3). A separate aliquot of MSE from IP3-treated microsomes was heated at 100 °C for 5 min (IP3/100°). MSE was then added to the cytoplasmic fraction for 1 h, and NF-kappa B binding activity was determined by EMSA. c, films from three different EMSAs were scanned, and densitometric analyses were performed. Data are the means ± S.E. (n = 3). *, p < 0.01 compared with control (Con); **, p < 0.01 compared with IP3 alone (analysis of variance with Scheffe's post-hoc test).


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

NF-kappa B is believed to play important roles in brain development and in neurodegenerative disorders (2, 51). In unstimulated cells, NF-kappa B subunits are present in the cytoplasm, including neurites and synapses, in an inactive form complexed with Ikappa Balpha (45, 52). Increases in cytosolic calcium levels had previously been associated with activation of NF-kappa B (41, 53-57); but it was not established if and how calcium itself activates NF-kappa B, and increased [Ca2+]i is an event common to several different NF-kappa B-activating pathways (24). Studies of other transcription factors such as CREB have shown that the source of calcium entry may affect which genes are transcribed through distinct DNA regulatory elements (44). To help elucidate the relationship between ER calcium release through IP3 receptors specifically and NF-kappa B activation, we conducted a series of experiments in cortical neurons and found that 1) inhibition of IP3 receptor channels reduces both basal and thapsigargin-induced NF-kappa B DNA-binding activity; 2) the decrease in NF-kappa B activity is independent of changes in intracellular calcium levels; 3) extracts from microsomes release a diffusible NF-kappa B-stimulating signal that is augmented by IP3 and thapsigargin and diminished by XeC; and 4) the ER-derived NF-kappa B-activating signal is not calcium. This factor appears to be regulated by IP3 receptor activity and/or the filling state of the IP3-sensitive pools of intracellular calcium. Thus, our data indicate that it is not the calcium release from ER stores that activates cytoplasmic NF-kappa B, but rather the decrease in intraluminal calcium that signals release of a diffusible NF-kappa B-activating factor from the ER.

We found that a concentration of XeC reported to selectively block IP3 calcium channels in a noncompetitive manner (36-38) can decrease the basal level of NF-kappa B activation. It has been shown that the constitutively active form of NF-kappa B in neurons is transcriptionally active and may drive basal expression of several different genes (58). Although the basis of this constitutive activity has been unclear, our data suggest that it is dependent upon IP3 receptor activation. It has been previously shown that there is a spontaneous release of calcium from IP3-sensitive calcium stores (59) resulting from a basal level of IP3 production and the ER luminal content of calcium. It should be emphasized that IP3 receptors can be activated in response to a broad range of stimuli present in neuronal cultures. IP3 is endogenously produced in cultures as result of the actions of growth factors, neuropeptides, and other bio-molecules coupled to phospholipase C-linked GTP-binding proteins. Activation of purinergic receptors and glutamate receptors, depolarization of the membranes, and synaptic activity will all activate the IP3 receptors present in the ER. According to our data, if the constitutive activity of IP3 receptors is blocked, the basal activation of NF-kappa B in neurons is largely abolished, strongly suggesting that the two events are functionally related.

Activation of TNF receptors results in recruitment of TNF receptor-associated death domain, which acts as an adaptor for TNF receptor-associated factor-2, which in turn mediates NF-kappa B activation (60-62). In our model, XeC significantly inhibited the ability of TNF-alpha to induce NF-kappa B. TNF-alpha does not evoke calcium transients over short time periods (63); however, it does activate phospholipase C (64) and can thereby activate ER IP3 receptors even in the absence of elevated intracellular calcium levels (65). Supporting this is the recent finding of Liu et al. (66) that activation of NF-kappa B in astrocytes by TNF-alpha is dependent upon metabotropic P2Y receptors. Glutamate, which causes a large influx of calcium in neurons, also greatly induces NF-kappa B DNA-binding activity (20, 67). XeC was able to totally abolish this induction by glutamate, although XeC treatment only partially attenuated the increase in intracellular calcium levels caused by glutamate. Glutamate induces ER calcium release by increasing intracellular calcium (68-70) and by stimulating IP3 production through phospholipase C activation (71, 72). Therefore, each of the inducers of NF-kappa B examined in this study (glutamate, TNF-alpha , and thapsigargin) have in common the ability to initiate calcium release from ER IP3-sensitive stores.

The cell-free system that was used as a model in our studies consisted of a membrane-free cytoplasmic fraction and an extract taken from ER-rich microsomes after treatment with agents that affect ER calcium pools. We manipulated the ER calcium regulatory proteins with specific agents: thapsigargin to irreversibly inhibit Ca2+-ATPases and to decrease intramicrosomal calcium maximally, XeC to specifically block calcium release from IP3 stores, IP3 to mimic the in vivo system of IP3 receptor activation, and ryanodine to examine the other major pool of ER calcium. Treatment of microsomes with thapsigargin resulted in release into MSE of a factor(s) that activates cytoplasmic NF-kappa B to a level 3-fold that of the control level. This level of activation is comparable to that seen in intact cultured cells exposed to agents that release ER calcium (Refs. 30 and 73 and this study). Conversely, treatment of microsomes with XeC totally abolished the stimulatory effect of MSE, resulting in NF-kappa B binding levels that were no different from the cytoplasm alone.

Addition of thapsigargin and XeC directly to the cytoplasmic extract did not alter NF-kappa B DNA-binding activity, indicating that these factors must work through microsomes to stimulate NF-kappa B. Furthermore, the fact that neither calcium nor BAPTA was able to directly affect NF-kappa B DNA-binding activity shows that the calcium released from the microsomes is not the factor that regulates NF-kappa B. Indeed, the role calcium plays in this paradigm seems to be as an intraluminal signal, such that the depletion of calcium from the IP3 pool is a signal for release of the NF-kappa B-activating factor. This is supported by the observation that direct activation of IP3 receptors on microsomes using IP3 itself led to MSE that had NF-kappa B-stimulating properties similar to those seen with thapsigargin. In addition, pretreatment of microsomes with XeC completely abolished this effect. Release of calcium by ER IP3 receptors results in a decrease in the pool of calcium in those ER stores, and it is this calcium depletion that apparently leads to release of the diffusible factor that stimulates NF-kappa B activity. Microsomes pretreated with XeC followed by calcium produced no NF-kappa B-stimulating activity, indicating that although calcium can directly modulate ER calcium release, it has no effect when IP3 receptors are blocked. Addition of ryanodine to microsomes did not result in an increase in NF-kappa B-stimulating activity in MSE, indicating that it is the ER IP3 pool specifically that regulates release of this factor. These findings reveal a heretofore unknown mechanism for modulation of NF-kappa B activity by the ER and suggest the presence of a novel factor released by microsomes that activates NF-kappa B. The identity of this factor remains to be determined, but it could conceivably be a protein because it is heat- and trypsin-sensitive and because previous studies have shown that luminal proteins are released from the ER in response to calcium depletion (74).

Increasing data implicate cell calcium-regulating mechanisms as having a central role in governing NF-kappa B activity. We have shown in our in vitro studies that calcium per se does not change NF-kappa B binding. However, our cell-free system examined only the NF-kappa B-signaling pathway from the ER to NF-kappa B activation. Indeed, in the whole cell, the hypothesis that it is the filling state of the ER IP3 pool that signals NF-kappa B activation would place calcium as a major upstream effector. Both IP3 and ryanodine receptors are sensitive to [Ca2+]i, as is the ER Ca2+-ATPase. In addition, IP3 production is sensitive to calcium levels (75, 76). In fact, in the absence of calcium, phospholipase C-mediated production of IP3 drops precipitously (77). Our data suggest that an array of signals ranging from neurotransmitters to neurotrophic factors and cytokines may modulate NF-kappa B activity, in part, by affecting ER calcium release. Both ER calcium release (78-80) and NF-kappa B activation (13, 16, 52, 81) play pivotal roles in regulating synaptic plasticity and survival of neurons during development of injury and disease conditions. In addition, an ER overload (unfolded protein) response occurs in cells exposed to a variety of stressors (82) and results in NF-kappa B activation by a mechanism involving release of calcium from the ER (41). Our findings therefore identify a novel signaling pathway whereby activation of IP3 receptors results in generation of a diffusible signal that activates a transcription factor known to play important roles in neuronal plasticity and survival.

    FOOTNOTES

* This work was supported by National Institutes of Health Grants NRSA467305 (to G. W. G.) and NS39184 (to J. D. G.) and by NIA, National Institutes of Health.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

These two authors contributed equally to this work.

** To whom correspondence should be addressed: Lab. of Neurosciences, NIA, GRC 4F02, 5600 Nathan Shock Dr., Baltimore, MD 21224. Tel.: 410-558-8463; Fax: 410-558-8465; E-mail: mattsonm@grc.nia.nih.gov.

Published, JBC Papers in Press, April 17, 2001, DOI 10.1074/jbc.M101315200

    ABBREVIATIONS

The abbreviations used are: NF-kappa B, nuclear factor-kappa B; TNF, tumor necrosis factor; [Ca2+]i, intracellular free calcium concentration; ER, endoplasmic reticulum; IP3, D-myo-inositol 1,4,5-trisphosphate; XeC, xestospongin C; BAPTA, 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid; EMSA, electrophoretic mobility shift assay; CREB, cAMP-responsive element-binding protein; MSE, microsomal extract.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1. Baeuerle, P. A., and Baltimore, D. (1996) Cell 87, 13-20[Medline] [Order article via Infotrieve]
2. Mattson, M. P., Culmsee, C., Yu, Z., and Camandola, S. (2000) J. Neurochem. 74, 443-456[CrossRef][Medline] [Order article via Infotrieve]
3. Kaltschmidt, C., Kaltschmidt, B., Neumann, H., Wekerle, H., and Baeuerle, P. A. (1994) Mol. Cell. Biol. 14, 3981-3992[Abstract]
4. Prasad, A. V., Pilcher, W. H., and Joseph, S. A. (1994) Neurosci. Lett. 170, 145-148[Medline] [Order article via Infotrieve]
5. Rong, Y., and Baudry, M. (1996) J. Neurochem. 67, 662-668[Medline] [Order article via Infotrieve]
6. Clemens, J. A., Stephenson, D. T., Dixon, E. P., Smalstig, E. B., Mincy, R. E., Rash, K. S., and Little, S. P. (1997) Brain Res. Mol. Brain Res. 48, 187-196[CrossRef][Medline] [Order article via Infotrieve]
7. Schneider, A., Martin-Villalba, A., Weih, F., Vogel, J., Wirth, T., and Schwaninger, M. (1999) Nat. Med. 5, 554-559[CrossRef][Medline] [Order article via Infotrieve]
8. Hunot, S., Brugg, B., Ricard, D., Michel, P. P., Muriel, M. P., Ruberg, M., Faucheux, B. A., Agid, Y., and Hirsch, E. C. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 7531-7536[Abstract/Free Full Text]
9. Kaltschmidt, B., Uherek, M., Volk, B., Baeuerle, P. A., and Kaltschmidt, C. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 2642-2647[Abstract/Free Full Text]
10. Akama, K. T., Albanese, C., Pestell, R. G., and Van Eldik, L. J. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 5795-5800[Abstract/Free Full Text]
11. Grilli, M., Pizzi, M., Memo, M., and Spano, P. (1996) Science 274, 1383-1385[Abstract/Free Full Text]
12. Barger, S. W., Horster, D., Furukawa, K., Goodman, Y., Krieglstein, J., and Mattson, M. P. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 9328-9332[Abstract]
13. Mattson, M. P., Goodman, Y., Luo, H., Fu, W., and Furukawa, K. (1997) J Neurosci. Res. 49, 681-697[CrossRef][Medline] [Order article via Infotrieve]
14. Taglialatela, G., Robinson, R., and Perez-Polo, J. R. (1997) J. Neurosci. Res. 47, 155-156[CrossRef][Medline] [Order article via Infotrieve]
15. Yu, Z., Zhou, D., Bruce-Keller, A. J., Kindy, M. S., and Mattson, M. P. (1999) J. Neurosci. 19, 8856-8865[Abstract/Free Full Text]
16. Albensi, B. C., and Mattson, M. P. (2000) Synapse 35, 151-159[CrossRef][Medline] [Order article via Infotrieve]
17. Hazan, U., Thomas, D., Alcami, J., Bachelerie, F., Israel, N., Yssel, H., Virelizier, J. L., and Arenzana-Seisdedos, F. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 7861-7865[Abstract]
18. Swingler, S., Easton, A., and Morris, A. (1992) AIDS Res. Hum. Retroviruses 8, 487-493[Medline] [Order article via Infotrieve]
19. Nonaka, M., and Huang, Z. M. (1990) Mol. Cell. Biol. 10, 6283-6289[Medline] [Order article via Infotrieve]
20. Kaltschmidt, C., Kaltschmidt, B., and Baeuerle, P. A. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 9618-9622[Abstract]
21. Carter, B. D., Kaltschmidt, C., Kaltschmidt, B., Offenhauser, N., Bohm- Matthaei, R., Baeuerle, P. A., and Barde, Y. A. (1996) Science 272, 542-545[Abstract]
22. Maggirwar, S. B., Sarmiere, P. D., Dewhurst, S., and Freeman, R. S. (1998) J. Neurosci. 18, 10356-10365[Abstract/Free Full Text]
23. Barger, S. W., and Mattson, M. P. (1996) Mol. Brain Res. 40, 116-126[Medline] [Order article via Infotrieve]
24. Ginn-Pease, M. E., and Whisler, R. L. (1998) Free Radic. Biol. Med. 25, 346-361[CrossRef][Medline] [Order article via Infotrieve]
25. Gius, D., Botero, A., Shah, S., and Curry, H. A. (1999) Toxicol. Lett. 106, 93-106[CrossRef][Medline] [Order article via Infotrieve]
26. Mercurio, F., and Manning, A. M. (1999) Oncogene 18, 6163-6171[CrossRef][Medline] [Order article via Infotrieve]
27. Kennedy, M. B. (1989) Trends Neurosci. 12, 417-420[CrossRef][Medline] [Order article via Infotrieve]
28. Berridge, M. J. (1998) Neuron 21, 13-26[Medline] [Order article via Infotrieve]
29. Verkhratsky, A., and Shmigol, A. (1996) Cell Calcium 19, 1-14[Medline] [Order article via Infotrieve]
30. Pahl, H. L., and Baeuerle, P. A. (1995) EMBO J. 14, 2580-2588[Abstract]
31. Pahl, H. L., and Baeuerle, P. A. (1997) Trends Biochem. Sci. 22, 63-67[CrossRef][Medline] [Order article via Infotrieve]
32. Mattson, M. P., Lovell, M. A., Furukawa, K, and Markesbery, W. R. (1995) J. Neurochem. 65, 1740-1751[Medline] [Order article via Infotrieve]
33. Baeuerle, P. A., and Baltimore, D. (1988) Cell 53, 211-217[Medline] [Order article via Infotrieve]
34. Chen, P. Y., Csutora, P., Veyna-Burke, N. A., and Marchase, R. B. (1998) Diabetes 47, 874-881[Abstract]
35. Glazner, G. W., Chan, S. L., Lu, C., and Mattson, M. P. (2000) J. Neurosci. 20, 3641-3649[Abstract/Free Full Text]
36. Gafni, J., Munsch, J. A., Lam, T. H., Catlin, M. C., Costa, L. G., Molinski, T. F., and Pessah, I. N. (1997) Neuron 19, 723-733[Medline] [Order article via Infotrieve]
37. Hu, Q., Deshpande, S., Irani, K., and Ziegelstein, R. C. (1999) J. Biol. Chem. 274, 33995-33998[Abstract/Free Full Text]
38. Ma, H.-T., Patterson, R. L., van Rossum, D. B., Birnbaumer, L., Mikoshiba, K., and Gill, D. L. (2000) Science 287, 1647-1651[Abstract/Free Full Text]
39. Thastrup, O., Cullen, P. J., Drobak, B. K., Hanley, M. R., and Dawson, A. P. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 2466-2470[Abstract]
40. Davidson, G. A., and Varhol, R. J. (1995) J. Biol. Chem. 270, 11731-11734[Abstract/Free Full Text]
41. Pahl, H. L., and Baeuerle, P. A. (1996) FEBS Lett. 392, 129-136[CrossRef][Medline] [Order article via Infotrieve]
42. Stevens, C. F. (1994) Neuron 13, 769-770[Medline] [Order article via Infotrieve]
43. Huang, E. P., and Stevens, C. F. (1998) Essays Biochem. 33, 165-178[Medline] [Order article via Infotrieve]
44. Bading, H., Ginty, D. D., and Greenberg, M. E. (1993) Science 260, 181-186[Medline] [Order article via Infotrieve]
45. Kaltschmidt, C., Kaltschmidt, B., and Baeuerle, P. A. (1993) Mech. Dev. 43, 135-147[CrossRef][Medline] [Order article via Infotrieve]
46. Guerrini, L., Molteni, A., Wirth, T., Kistler, B., and Blasi, F. (1997) J. Neurosci. 17, 6057-6063[Abstract/Free Full Text]
47. Glazner, G. W., Camandola, S., and Mattson, M. P. (2000) J. Neurochem. 75, 101-108[CrossRef][Medline] [Order article via Infotrieve]
48. May, W., and Bisby, M. A. (1998) Brain Res. 797, 243-254[CrossRef][Medline] [Order article via Infotrieve]
49. Deisseroth, K., Bito, H., and Tsien, R. W. (1996) Neuron 16, 89-101[Medline] [Order article via Infotrieve]
50. Chan, S. L., Mayne, M., Holden, C. P., Geiger, J. D., and Mattson, M. P. (2000) J. Biol. Chem. 275, 18195-18200[Abstract/Free Full Text]
51. O'Neill, L. A. J., and Kaltschmidt, C. (1997) Trends Neurosci. 20, 252-258[CrossRef][Medline] [Order article via Infotrieve]
52. Meberg, P. J., Kinney, W. R., Valcourt, E. G., and Routtenberg, A. (1996) Mol. Brain Res. 38, 179-190[Medline] [Order article via Infotrieve]
53. Kanno, T., and Siebenlist, U. (1996) J. Immunol. 157, 5277-5283[Abstract]
54. Sen, C. K., Roy, S., and Packer, L. (1996) FEBS Lett. 385, 58-62[CrossRef][Medline] [Order article via Infotrieve]
55. Shatrov, V. A., Lehmann, V., and Chouaib, S. (1997) Biochem. Biophys. Res. Commun. 234, 121-124[CrossRef][Medline] [Order article via Infotrieve]
56. Lazaar, A. L., Amrani, Y., Hsu, J., Panettieri, R. A., Jr., Fanslow, W. C., Albelda, S. M., and Pure, E. (1998) J. Immunol. 161, 3120-3127[Abstract/Free Full Text]
57. Quinlan, K. L., Naik, S. M., Cannon, G., Armstrong, C. A., Bunnett, N. W., Ansel, J. C., and Caughman, S. W. (1999) J. Immunol. 163, 5656-5665[Abstract/Free Full Text]
58. Rattner, A., Korner, M., Walker, M. D., and Citri, Y. (1993) EMBO J. 12, 4261-4267[Abstract]
59. Missiaen, L., Taylor, C. W., and Berridge, M. J. (1991) Nature 352, 241-244[CrossRef][Medline] [Order article via Infotrieve]
60. Rothe, M., Wong, S. C., Henzel, W. J., and Goeddel, D. V. (1994) Cell 78, 681-692[Medline] [Order article via Infotrieve]
61. Hsu, H., Shu, S. B., Pan, M. G., Baichwal, V., and Goeddel, D. V. (1996) Cell 84, 299-308[Medline] [Order article via Infotrieve]
62. Hsu, H., Xiong, J., and Goeddel, D. V. (1995) Cell 81, 495-504[Medline] [Order article via Infotrieve]
63. Amrani, Y., Martinet, N., and Bronner, C. (1995) Br. J. Pharmacol. 114, 4-5[Abstract]
64. Schutze, S., Wiegmann, K., Machleidt, T., and Kronke, M. (1995) Immunobiology 93, 193-203
65. Bouchelouche, P. N., Bendtzen, K., Bak, S., and Nielsen, O. H. (1990) Cell. Signal. 2, 479-487[Medline] [Order article via Infotrieve]
66. Liu, J. S. H., John, G. R., Sikora, A., Sunheee, C. L., and Brosnan, C. F. (2000) J. Neurosci. 20, 5292-5299[Abstract/Free Full Text]
67. Guerrini, L., Blasi, F., and Denis-Donini, D. S. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 9077-9081[Abstract]
68. Kato, B. M., and Rubel, E. W. (1999) J. Neurophysiol. 81, 1587-1596[Abstract/Free Full Text]
69. Nakamura, T., Barbara, J. G., Nakamura, K., and Ross, W. N. (1999) Neuron 24, 727-737[Medline] [Order article via Infotrieve]
70. Nakamura, T., Nakamura, K., Lasser-Ross, N., Barbara, J. G., Sandler, V. M., and Ross, W. N. (2000) J. Neurosci. 20, 8365-8376[Abstract/Free Full Text]
71. Recasens, M., and Vignes, M. (1995) Ann. N. Y. Acad. Sci. 757, 418-429[Medline] [Order article via Infotrieve]
72. Liu, H. N., Molina-Holgado, E., and Almazan, G. (1997) Eur. J. Pharmacol. 338, 277-287[CrossRef][Medline] [Order article via Infotrieve]
73. Sei, Y., and Reich, H. (1995) Immunol. Lett. 45, 75-80[CrossRef][Medline] [Order article via Infotrieve]
74. Booth, C., and Koch, G. L. E. (1989) Cell 59, 729-737[Medline] [Order article via Infotrieve]
75. del Rio, E., Nicholls, D. G., and Downes, C. P. (1994) J. Neurochem. 63, 535-543[Medline] [Order article via Infotrieve]
76. Kim, Y. H., Park, T. J., Lee, Y. H., Baek, K. J., Suh, P. G., Ryu, S. H., and Kim, K. T. (1999) J. Biol. Chem. 274, 26127-26134[Abstract/Free Full Text]
77. Hughes, A. R., and Putney, J. W., Jr. (1990) Environ. Health Perspect. 84, 141-147[Medline] [Order article via Infotrieve]
78. Reyes, M., and Stanton, P. K. (1996) J. Neurosci. 16, 5951-5960[Abstract/Free Full Text]
79. Harris, K. M. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 12213-12215[Free Full Text]
80. Yao, C. J., Lin, C. W., and Lin-Shiau, S. Y. (1999) J. Neurochem. 73, 457-465[CrossRef][Medline] [Order article via Infotrieve]
81. Hamanoue, M., Middleton, G., Wyatt, S., Jaffray, E., Hay, R. T., and Davies, A. M. (1999) Mol. Cell. Neurosci. 14, 28-40[CrossRef][Medline] [Order article via Infotrieve]
82. Chapman, R., Sidrauski, C., and Walter, P. (1998) Annu. Rev. Cell Dev. Biol. 14, 459-485[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.